SATB2 Protein Expression by Immunohistochemistry is a Sensitive and Specific Marker of Appendiceal and Rectosigmoid Well Differentiated Neuroendocrine Tumors.
Neuroendocrine neoplasms (NN)s range from well to poorly differentiated and indolent to highly aggressive. The site of origin in metastatic NNs has therapeutic and prognostic implications. SATB2 is a transcriptional regulator involved in osteoblastic and neuronal differentiation and a sensitive and specific marker of colorectal epithelium. This study aimed to evaluate the expression of SATB2 in NNs from various primary sites and its utility as a marker in determining the site of origin of these neoplasms. SATB2 immunohistochemistry was performed on 266 NNs, including lung small cell carcinomas (N=39) and carcinoids (N=30); bladder (N=21) and prostate (N=31) small cell carcinomas; and gastrointestinal (GI)/pancreatic NNs of various primary sites (N=145) consisting of well differentiated neuroendocrine tumors (WDNET)s (N=124) and poorly differentiated neuroendocrine carcinomas (PDNEC)s (N=21). SATB2 was expressed in prostatic (10/31, 32%) and bladder (8/21, 38%) small carcinomas, and lung carcinoid tumors (1/30, 3%) and small cell carcinomas (8/39, 21%). Among primary GI NNs, SATB2 was expressed in 37/124 (30%) WDNETs and 4/21 (19%) PDNECs. Of the former, 15/15 (100%) rectal/rectosigmoid and 22/22 (100%) appendiceal neoplasms expressed SATB2. By receiver operator characteristic analysis, SATB2 was a sensitive and specific marker for rectal (100.0%; 80.0%) and appendiceal (100.0%; 84.5%) WDNETs, respectively. In summary, SATB2 is a sensitive and specific marker for rectal/rectosigmoid and appendiceal WDNETs and may represent a useful diagnostic tool when these sites of origin are considered in the differential diagnosis.